We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

65 hedge funds and large institutions have $953M invested in China Biologic Products Holdings, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 15

32% more capital invested

Capital invested by funds: $724M → $953M (+$229M)

20% more funds holding

Funds holding: 5465 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

80% less call options, than puts

Call options by funds: $807K | Put options by funds: $4.05M

Holders
65
Holders Change
+11
Holders Change %
+20.37%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
27
Reduced
15
Closed
5
Calls
$807K
Puts
$4.05M
Net Calls
-$3.24M
Net Calls Change
-$2.44M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$739M
VAM
2
Visium Asset Management
New York
$27.2M -$154K -2,493 -0.6%
Renaissance Technologies
3
Renaissance Technologies
New York
$18.6M +$3.32M +53,500 +24%
Fidelity International
4
Fidelity International
Bermuda
$16.4M +$1M +16,154 +7%
Morgan Stanley
5
Morgan Stanley
New York
$12.3M +$3.66M +59,111 +48%
MICM
6
Matthews International Capital Management
California
$10.3M +$9.53M +153,854 New
EMR
7
Errol M. Rudman
$7.41M
DKCM
8
Davidson Kempner Capital Management
New York
$7.13M +$795K +12,821 +14%
Deutsche Bank
9
Deutsche Bank
Germany
$6.85M +$6.31M +101,844 New
UBS Group
10
UBS Group
Switzerland
$6.79M +$6.26M +101,000 New
LBA
11
Letko, Brosseau & Associates
Quebec, Canada
$6.51M
ACM
12
Apex Capital Management
Ohio
$6.14M +$1.35M +21,801 +31%
CAM
13
Cormorant Asset Management
Massachusetts
$6.05M -$310K -5,000 -5%
PI
14
Putnam Investments
Massachusetts
$5.64M +$726K +11,719 +16%
William Blair & Company
15
William Blair & Company
Illinois
$5.26M +$25K +404 +0.5%
PA
16
Perceptive Advisors
New York
$4.98M +$4.44M +71,623 +2,984%
Invesco
17
Invesco
Georgia
$4.52M -$1.11M -17,924 -21%
Ameriprise
18
Ameriprise
Minnesota
$4.23M -$497K -8,023 -11%
GPGA
19
Grandeur Peak Global Advisors
Utah
$4.03M -$57.9K -934 -2%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$3.75M +$564K +9,100 +20%
HSBC Holdings
21
HSBC Holdings
United Kingdom
$3.36M -$73.4K -1,185 -2%
OAM
22
Oberweis Asset Management
Illinois
$3.36M +$3.1M +50,000 New
BIT
23
BlackRock Institutional Trust
California
$3.3M -$509K -8,206 -14%
AGA
24
Altrinsic Global Advisors
Connecticut
$3.15M +$764K +12,326 +36%
GPCM
25
Granite Point Capital Management
Massachusetts
$2.69M +$310K +5,000 +14%

CBPO Hedge Fund Activity: Q4 2014 in Review

65 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2014, worth a combined $953M — up 32% from $724M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CBPO positions and 5 closed out — a net gain of 12 holders — while 27 added to existing stakes and 15 trimmed.

The largest buyer was Matthews International Capital Management, opening a new position worth an estimated $9.53M. The largest seller was Invesco, cutting an estimated $1.11M.

  • 65 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2014, up from 54 in Q3 2014.
  • Funds reported $953M of China Biologic Products Holdings, Inc. stock for Q4 2014, up 32% quarter-over-quarter.
  • 17 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2014 and 5 closed out, a net change of +12 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q4 2014 was Matthews International Capital Management, an estimated $9.53M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q4 2014 was Invesco, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2014.